Incannex Healthcare Inc.

IXHL · Nasdaq · SIC 2834: Pharmaceutical Preparations
167
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs. IHL-42X, our drug candidate in a pivotal Phase 2/3 clinical trial for the treatment of obstructive sleep apnea (OSA) is an oral fixed-dose combination of dronabinol and acetazolamide designed to act synergistically by targeting two different physiological pathways associated with the intermittent hypoxia and ...

Next Earnings

Q2 FY2026 — expected 2026-08-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionIXHLdiscussed_in_filing Artificial Intelligence
topic_mentionIXHLdiscussed_in_filing Cybersecurity
topic_mentionIXHLdiscussed_in_filing Trusted Computing
topic_mentionIXHLdiscussed_in_filing Blockchain & Crypto
topic_mentionIXHLdiscussed_in_filing Regulation
topic_mentionIXHLdiscussed_in_filing Healthcare & Bio
topic_mentionIXHLdiscussed_in_filing Sovereign & Government
topic_mentionIXHLdiscussed_in_filing Artificial Intelligence
topic_mentionIXHLdiscussed_in_filing Cybersecurity
topic_mentionIXHLdiscussed_in_filing Trusted Computing
topic_mentionIXHLdiscussed_in_filing Blockchain & Crypto
topic_mentionIXHLdiscussed_in_filing Regulation
topic_mentionIXHLdiscussed_in_filing Healthcare & Bio
topic_mentionIXHLdiscussed_in_filing Sovereign & Government
topic_mentionIXHLdiscussed_in_filing Artificial Intelligence
topic_mentionIXHLdiscussed_in_filing Cybersecurity
topic_mentionIXHLdiscussed_in_filing Trusted Computing
topic_mentionIXHLdiscussed_in_filing Blockchain & Crypto
topic_mentionIXHLdiscussed_in_filing Regulation
topic_mentionIXHLdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-09-292025-06-300001213900-25-092837EDGAR87K words
2024-09-302024-06-300001213900-24-082937EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-132025-12-310001213900-26-015867EDGAR18K words
2025-11-142025-09-300001213900-25-110299EDGAR—
2025-05-152025-03-310001213900-25-043682EDGAR—
2025-02-142024-12-310001213900-25-013783EDGAR—
2024-11-142024-09-300001213900-24-098421EDGAR—
2024-05-152024-03-310001213900-24-043391EDGAR—
2024-02-142023-12-310001213900-24-013611EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001213900-26-035161EDGAR1K words
2026-03-250001213900-26-033842EDGAR—
2026-03-180001213900-26-029761EDGAR—
2026-03-170001213900-26-028661EDGAR—
2026-03-120001213900-26-026645EDGAR—
2026-03-120001213900-26-026644EDGAR—
2026-02-250001213900-26-020127EDGAR—
2026-01-290001213900-26-009160EDGAR—
2026-01-220001213900-26-006448EDGAR—
2026-01-160001213900-26-004866EDGAR—

167 total filings indexed. 148 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001873875
TickerIXHL
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 0337809c53988ec57e1f6a47a8300a67e30aa7866755a48d310de35cdf7582d5
parent: e8f0b0047f537346f08ebb61fcf2c8b0e3448809fe996371f9c81c086e1dfe5e
content hash: daf675321017985df47776c083070c2dfacaa9ef96edb1a06d4f02e6b884f53d
signed: 2026-04-13T04:45:47.098Z
sources: 9 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf